Moderna Inc'smessenger RNA-based experimental seasonal flu vaccine has produced robust antibodies against all four strains of the influenza virus in an early stage study, the vaccine maker said on Friday.
A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvicmessenger RNA-based experimental seasonal flu vaccine has produced robust antibodies against all four strains of the influenza virus in an early stage study, the vaccine maker said on Friday.
The early-stage study is ongoing and a mid-stage study testing of the vaccine, mRNA-1010, is now fully enrolled, the company said., that are also testing their flu vaccine based on messenger RNA.Moderna also said it was developing a pan-respiratory annual booster vaccine, which would target multiple viruses including COVID-19, flu and Respiratory syncytial virus."Even before the COVID-19 pandemic, approximately three million people died each year due to respiratory infections ...